Metabolic tumor volume predicts outcome in patients with advanced stage follicular lymphoma from the RELEVANCE trial
-
Published:2024-01
Issue:1
Volume:35
Page:130-137
-
ISSN:0923-7534
-
Container-title:Annals of Oncology
-
language:en
-
Short-container-title:Annals of Oncology
Author:
Cottereau A.S.ORCID,
Rebaud L.ORCID,
Trotman J.,
Feugier P.,
Nastoupil L.J.,
Bachy E.,
Flinn I.W.,
Haioun C.,
Ysebaert L.,
Bartlett N.L.,
Tilly H.,
Casasnovas O.,
Ricci R.,
Portugues C.,
Buvat I.,
Meignan M.,
Morschhauser F.ORCID
Funder
Celgene Corporation
Subject
Oncology,Hematology
Reference31 articles.
1. Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National LymphoCare Study;Casulo;J Clin Oncol,2015
2. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification;Cheson;J Clin Oncol,2014
3. Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group;Barrington;J Clin Oncol,2014
4. Baseline metabolic tumor volume predicts outcome in high-tumor-burden follicular lymphoma: a pooled analysis of three multicenter studies;Meignan;J Clin Oncol,2016
5. Total tumor burden in lymphoma - an evolving strong prognostic parameter;Meignan;Br J Radiol,2021
Cited by
7 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献